[go: up one dir, main page]

WO2008153029A1 - 特異的遺伝子発現方法 - Google Patents

特異的遺伝子発現方法 Download PDF

Info

Publication number
WO2008153029A1
WO2008153029A1 PCT/JP2008/060618 JP2008060618W WO2008153029A1 WO 2008153029 A1 WO2008153029 A1 WO 2008153029A1 JP 2008060618 W JP2008060618 W JP 2008060618W WO 2008153029 A1 WO2008153029 A1 WO 2008153029A1
Authority
WO
WIPO (PCT)
Prior art keywords
expression
specific gene
oligomeric protein
natural oligomeric
endogenous polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/060618
Other languages
English (en)
French (fr)
Inventor
Junichi Mineno
Sachiko Okamoto
Risa Sumioka
Masanari Kitagawa
Hiroshi Shiku
Ikunoshin Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Mie University NUC
Original Assignee
Takara Bio Inc
Mie University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc, Mie University NUC filed Critical Takara Bio Inc
Priority to JP2009519261A priority Critical patent/JP5271901B2/ja
Priority to CN2008801029989A priority patent/CN101815785B/zh
Priority to US12/664,133 priority patent/US9051391B2/en
Priority to EP08777135.8A priority patent/EP2172547B1/en
Priority to KR1020107000445A priority patent/KR101363928B1/ko
Publication of WO2008153029A1 publication Critical patent/WO2008153029A1/ja
Anticipated expiration legal-status Critical
Priority to US14/701,929 priority patent/US9296807B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　本発明は、非天然のオリゴマータンパク質を発現する細胞であって、天然のオリゴマータンパク質を構成する少なくとも１つの内在性ポリペプチドに対応する外来性ポリペプチドをコードする遺伝子が導入されており、かつ前記内在性ポリペプチドの発現が抑制されていることを特徴とする細胞を提供する。
PCT/JP2008/060618 2007-06-11 2008-06-10 特異的遺伝子発現方法 Ceased WO2008153029A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2009519261A JP5271901B2 (ja) 2007-06-11 2008-06-10 特異的遺伝子発現方法
CN2008801029989A CN101815785B (zh) 2007-06-11 2008-06-10 特异性基因表达的方法
US12/664,133 US9051391B2 (en) 2007-06-11 2008-06-10 Method for expression of specific gene
EP08777135.8A EP2172547B1 (en) 2007-06-11 2008-06-10 Method for expression of specific gene
KR1020107000445A KR101363928B1 (ko) 2007-06-11 2008-06-10 특이적 유전자 발현 방법
US14/701,929 US9296807B2 (en) 2007-06-11 2015-05-01 Method for expression of specific gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-154351 2007-06-11
JP2007154351 2007-06-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/664,133 A-371-Of-International US9051391B2 (en) 2007-06-11 2008-06-10 Method for expression of specific gene
US14/701,929 Division US9296807B2 (en) 2007-06-11 2015-05-01 Method for expression of specific gene

Publications (1)

Publication Number Publication Date
WO2008153029A1 true WO2008153029A1 (ja) 2008-12-18

Family

ID=40129634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060618 Ceased WO2008153029A1 (ja) 2007-06-11 2008-06-10 特異的遺伝子発現方法

Country Status (6)

Country Link
US (2) US9051391B2 (ja)
EP (2) EP3031916B1 (ja)
JP (2) JP5271901B2 (ja)
KR (1) KR101363928B1 (ja)
CN (1) CN101815785B (ja)
WO (1) WO2008153029A1 (ja)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101249A1 (ja) 2009-03-06 2010-09-10 国立大学法人三重大学 Ｔ細胞の機能増強方法
WO2012046727A1 (ja) 2010-10-05 2012-04-12 タカラバイオ株式会社 ウイルスベクターの製造方法
US20120321667A1 (en) * 2009-10-29 2012-12-20 Sentman Charles L T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
JP2017505621A (ja) * 2014-01-29 2017-02-23 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体を発現する細胞を生産する方法および組成物
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
WO2018143454A1 (ja) 2017-02-06 2018-08-09 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
JP2019509764A (ja) * 2016-03-15 2019-04-11 マックス−デルブリュック−セントラム フュール モルキュラー メディツィーン イン デル ヘルムホルツ−ゲマインシャフトＭａｘ−Ｄｅｌｂｒｕｃｋ−Ｃｅｎｔｒｕｍ Ｆｕｒ Ｍｏｌｅｋｕｌａｒｅｍｅｄｉｚｉｎ Ｉｎ Ｄｅｒｈｅｌｍｈｏｌｔｚ−Ｇｅｍｅｉｎｓｃｈａｆｔ 初代細胞のためのトランスポゾンに基づく転移システム
WO2019131770A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 核酸含有脂質ナノ粒子及びその用途
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2020013315A1 (ja) 2018-07-13 2020-01-16 国立大学法人京都大学 γδＴ細胞の製造方法
WO2020080475A1 (ja) 2018-10-18 2020-04-23 武田薬品工業株式会社 Ｔ細胞の活性化／増殖方法
WO2020262540A1 (ja) 2019-06-26 2020-12-30 武田薬品工業株式会社 トランスフェクション方法
WO2021106832A1 (ja) 2019-11-25 2021-06-03 国立大学法人京都大学 Ｔ細胞マスターセルバンク
US20220056409A1 (en) * 2009-10-29 2022-02-24 The Trustees Of Dartmouth College T-cell receptor-deficient t cell compositions
WO2022210581A1 (ja) 2021-03-31 2022-10-06 昭和電工マテリアルズ株式会社 情報管理装置及びコンピュータプログラム
WO2023022235A1 (ja) 2021-08-20 2023-02-23 大塚製薬株式会社 組み合わせ医薬

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5271901B2 (ja) * 2007-06-11 2013-08-21 タカラバイオ株式会社 特異的遺伝子発現方法
EP3208339B1 (en) 2008-09-15 2019-05-01 The Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP6415322B2 (ja) 2011-09-15 2018-10-31 アメリカ合衆国 Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
US9399780B2 (en) 2012-03-22 2016-07-26 Takara Bio Inc. Method for producing viral vector
US9822355B2 (en) 2012-11-27 2017-11-21 Children's Medical Center Corporation Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
JP6346266B2 (ja) * 2013-03-21 2018-06-20 サンガモ セラピューティクス， インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
CN106794260B (zh) 2014-04-25 2021-02-23 儿童医疗中心有限公司 治疗血红蛋白病的组合物和方法
US11572543B2 (en) 2015-05-08 2023-02-07 The Children's Medical Center. Corporation Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
PT3443075T (pt) 2016-04-15 2022-12-16 Memorial Sloan Kettering Cancer Center Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
US12522811B2 (en) 2018-05-01 2026-01-13 The Children's Medical Center Corporation Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
US12350284B2 (en) 2018-05-02 2025-07-08 The Children's Medical Center Corporation BCL11A microRNAs for treating hemoglobinopathies
EP3935177A4 (en) * 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
SG11202109591QA (en) 2019-03-04 2021-10-28 Univ Health Network T cell receptors and methods of use thereof
KR20210149051A (ko) * 2019-03-04 2021-12-08 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
CN113795583A (zh) * 2019-03-04 2021-12-14 大学健康网络 T细胞受体及其使用方法
CA3132435A1 (en) * 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
US20220168347A1 (en) * 2019-03-04 2022-06-02 University Health Network T cell receptors and methods of use thereof
AU2020231927A1 (en) * 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
AU2020245270A1 (en) * 2019-03-25 2021-10-14 University Health Network T cell receptors and methods of use thereof
KR20220038776A (ko) * 2019-07-30 2022-03-29 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
WO2021019471A1 (en) * 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
US20220281942A1 (en) * 2019-07-30 2022-09-08 University Health Network T cell receptors and methods of use thereof
KR20220121844A (ko) * 2019-12-23 2022-09-01 베르사멥 아게 유전자의 발현을 동시에 조절하기 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230458B1 (hu) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
JP5271901B2 (ja) * 2007-06-11 2013-08-21 タカラバイオ株式会社 特異的遺伝子発現方法

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY
BLOOD, vol. 103, 2003, pages 3530 - 3540
BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 1310
CANCER RES., vol. 66, 2006, pages 3331 - 3337
FUJIO K. ET AL.: "Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex", J. IMMUNOL., vol. 165, no. 1, 2000, pages 528 - 532, XP002414018 *
GENE THERAPY, vol. 7, 2000, pages 1369 - 1377
GENE THERAPY, vol. 7, 2000, pages 797 - 804
J. CLIN. INVEST., vol. 114, 2004, pages 1774 - 1781
J. IMMUNOL., vol. 163, 1999, pages 507 - 513
J. IMMUNOL., vol. 170, 2003, pages 2186 - 2194
PINTHUS J.H. ET AL.: "Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes", J. CLIN. INVEST., vol. 114, no. 12, 2004, pages 1774 - 1781, XP009135044 *
POQULIS R.J. AND PEASE L.R.: "A Retroviral Vector that Directs Stimulatenous Expression of alpha and B T Cell REceptor Genes", HUM. GENE THER., vol. 9, 1998, pages 2299 - 2304, XP009135048 *
See also references of EP2172547A4 *
VAN DER VEKEN L.T. ET AL.: "alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity", CANCER RES., vol. 66, no. 6, 2006, pages 3331 - 3337, XP002408981 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017035090A (ja) * 2009-03-06 2017-02-16 国立大学法人三重大学 Ｔ細胞の機能増強方法
WO2010101249A1 (ja) 2009-03-06 2010-09-10 国立大学法人三重大学 Ｔ細胞の機能増強方法
JP2018145205A (ja) * 2009-03-06 2018-09-20 国立大学法人三重大学 Ｔ細胞の機能増強方法
US9603874B2 (en) 2009-03-06 2017-03-28 Takara Bio Inc. Method for enhancing a function of a T cell
US9181525B2 (en) 2009-03-06 2015-11-10 Mie University Method for enhancing a function of a T cell
US10689617B1 (en) 2009-10-29 2020-06-23 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US11834676B2 (en) 2009-10-29 2023-12-05 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9181527B2 (en) * 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US9663763B2 (en) 2009-10-29 2017-05-30 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US12492375B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9821011B1 (en) 2009-10-29 2017-11-21 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9822340B1 (en) 2009-10-29 2017-11-21 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US12291723B2 (en) 2009-10-29 2025-05-06 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9938497B2 (en) 2009-10-29 2018-04-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US9957480B2 (en) 2009-10-29 2018-05-01 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US12168780B2 (en) 2009-10-29 2024-12-17 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US20120321667A1 (en) * 2009-10-29 2012-12-20 Sentman Charles L T cell receptor-deficient t cell compositions
US12146158B2 (en) 2009-10-29 2024-11-19 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US12031156B2 (en) 2009-10-29 2024-07-09 Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US10689619B2 (en) 2009-10-29 2020-06-23 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US20220056409A1 (en) * 2009-10-29 2022-02-24 The Trustees Of Dartmouth College T-cell receptor-deficient t cell compositions
US11136549B2 (en) 2009-10-29 2021-10-05 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US10689616B1 (en) 2009-10-29 2020-06-23 The Trustees Of Dartmouth College T-cell receptor-deficient t cell compositions
US10689618B2 (en) 2009-10-29 2020-06-23 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2012046727A1 (ja) 2010-10-05 2012-04-12 タカラバイオ株式会社 ウイルスベクターの製造方法
US10682378B2 (en) 2011-08-31 2020-06-16 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US11872248B2 (en) 2011-08-31 2024-01-16 The Trustees Of Dartmouth College Nucleic acids encoding chimeric receptor comprising NKP30 receptor and CD28 and CD3 zeta domains and human T cell containing
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
US12065492B2 (en) 2012-05-07 2024-08-20 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
US11034766B2 (en) 2012-05-07 2021-06-15 Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
JP2017505621A (ja) * 2014-01-29 2017-02-23 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体を発現する細胞を生産する方法および組成物
US11185577B2 (en) 2015-05-05 2021-11-30 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10849965B2 (en) 2015-05-05 2020-12-01 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11925679B2 (en) 2015-05-05 2024-03-12 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
JP7053053B2 (ja) 2016-03-15 2022-04-12 マックス－デルブリュック－セントラム フュール モルキュラー メディツィーン イン デル ヘルムホルツ－ゲマインシャフト 初代細胞のためのトランスポゾンに基づく転移システム
JP2019509764A (ja) * 2016-03-15 2019-04-11 マックス−デルブリュック−セントラム フュール モルキュラー メディツィーン イン デル ヘルムホルツ−ゲマインシャフトＭａｘ−Ｄｅｌｂｒｕｃｋ−Ｃｅｎｔｒｕｍ Ｆｕｒ Ｍｏｌｅｋｕｌａｒｅｍｅｄｉｚｉｎ Ｉｎ Ｄｅｒｈｅｌｍｈｏｌｔｚ−Ｇｅｍｅｉｎｓｃｈａｆｔ 初代細胞のためのトランスポゾンに基づく転移システム
WO2018143454A1 (ja) 2017-02-06 2018-08-09 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
WO2019131770A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 核酸含有脂質ナノ粒子及びその用途
WO2020013315A1 (ja) 2018-07-13 2020-01-16 国立大学法人京都大学 γδＴ細胞の製造方法
WO2020080475A1 (ja) 2018-10-18 2020-04-23 武田薬品工業株式会社 Ｔ細胞の活性化／増殖方法
WO2020262540A1 (ja) 2019-06-26 2020-12-30 武田薬品工業株式会社 トランスフェクション方法
EP4067490A1 (en) 2019-11-25 2022-10-05 Kyoto University T-cell master cell bank
WO2021106832A1 (ja) 2019-11-25 2021-06-03 国立大学法人京都大学 Ｔ細胞マスターセルバンク
WO2022210581A1 (ja) 2021-03-31 2022-10-06 昭和電工マテリアルズ株式会社 情報管理装置及びコンピュータプログラム
US12505904B2 (en) 2021-03-31 2025-12-23 National Cancer Center Information management apparatus and non-transitory computer-readable recording medium
WO2023022235A1 (ja) 2021-08-20 2023-02-23 大塚製薬株式会社 組み合わせ医薬

Also Published As

Publication number Publication date
JPWO2008153029A1 (ja) 2010-08-26
EP2172547B1 (en) 2016-01-06
US9051391B2 (en) 2015-06-09
EP3031916A1 (en) 2016-06-15
KR20100058447A (ko) 2010-06-03
JP2013162797A (ja) 2013-08-22
JP5828861B2 (ja) 2015-12-09
CN101815785B (zh) 2013-06-19
US20150232530A1 (en) 2015-08-20
JP5271901B2 (ja) 2013-08-21
EP3031916B1 (en) 2017-06-07
US20100273213A1 (en) 2010-10-28
KR101363928B1 (ko) 2014-02-19
US9296807B2 (en) 2016-03-29
CN101815785A (zh) 2010-08-25
EP2172547A1 (en) 2010-04-07
EP2172547A4 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
WO2008153029A1 (ja) 特異的遺伝子発現方法
WO2009020144A1 (ja) 異種タンパク質の製造方法
WO2008065200A8 (en) Dnase expression in recombinant host cells
WO2009054433A1 (ja) 異種タンパク質製造のための細胞及びそれを用いた製造方法
NZ600585A (en) Expression of hexose kinase in recombinant host cells
WO2008104890A3 (en) Compositions and methods for producing apolipoprotein
WO2010107303A3 (en) Chrysosporium lucknowense protein production system
WO2006136084A8 (en) Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
PL1948789T3 (pl) Sposób wytwarzania ciągłych ludzkich linii komórkowych
IL189193A0 (en) Transplastomic plants expressing lumen-targeted protein
WO2005100573A3 (en) Fungal promoters for expressing a gene in a fungal cell
WO2011100566A3 (en) Methods for identifying and isolating cells expressing a polypeptide
WO2011103300A3 (en) Improving activity of fe-s cluster requiring proteins
WO2009149956A3 (en) Fusion protein and use thereof
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
WO2009158627A3 (en) Cellulosic protein expression in yeast
MX2009008021A (es) Produccion de una aciltransferasa de lipido de celulas de bacillus licheniformis transformadas.
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
WO2009126463A3 (en) Filamentous fungi with inactivated protease genes for altered protein production
WO2012057567A3 (ko) Klotho 유전자를 포함하는 피부 활성물질 탐색용 키트 및 이를 이용하여 피부 활성물질을 탐색하는 방법
TNSN07090A1 (en) Novel laccase enzyme and use thereof
GB2458419A (en) Vector for expressing NC protein of HIV and method for producing NC protein using the same
WO2007113336A3 (de) Funktionale expression von triacylglycerol-lipasen
WO2011117728A3 (en) Novel cbh1-eg1 fusion proteins and use thereof
WO2012125720A3 (en) Polypeptides having immunoactivating activity and methods of producing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880102998.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777135

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009519261

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008777135

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107000445

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12664133

Country of ref document: US